FDA Gives Orphan Drug Status to Potential Multiple Myeloma Immunotherapy

FDA Gives Orphan Drug Status to Potential  Multiple Myeloma Immunotherapy

283190

FDA Gives Orphan Drug Status to Potential Multiple Myeloma Immunotherapy

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Harpoon Therapeutics‘ investigational immunotherapy HPN217 as a possible treatment of multiple myeloma. The designation encourages the development of potential therapies for rare and serious diseases by granting them various financial and regulatory benefits. These include exemptions from certain fees, trial protocol assistance, and seven years of market exclusivity upon approval. “Orphan Drug Designation for multiple myeloma represents a significant milestone in the development of HPN217…

You must be logged in to read/download the full post.